Chest
Volume 129, Issue 1, Supplement, January 2006, Pages 169S-173S
Journal home page for Chest

Supplement
Diagnosis and Management of Cough: ACCP Evidence-Based Clinical Practice Guidelines
Angiotensin-Converting Enzyme Inhibitor-Induced Cough: ACCP Evidence-Based Clinical Practice Guidelines

https://doi.org/10.1378/chest.129.1_suppl.169SGet rights and content

Background:

A dry, persistent cough is a well-described class effect of the angiotensin-converting enzyme (ACE) inhibitor medications. The mechanism of ACE inhibitor-induced cough remains unresolved, but likely involves the protussive mediators bradykinin and substance P, agents that are degraded by ACE and therefore accumulate in the upper respiratory tract or lung when the enzyme is inhibited, and prostaglandins, the production of which may be stimulated by bradykinin.

Methods:

Data for this review were obtained from a National Library of Medicine (PubMed) search, which was performed in May 2004, of the literature published in the English language from 1985 to 2004, using the search terms “angiotensin-converting enzyme,” “angiotensin converting enzyme inhibitors,” and “cough.”

Results:

The incidence of ACE inhibitor-induced cough has been reported to be in the range of 5 to 35% among patients treated with these agents. However, a much lower incidence has been described in studies of patients presenting for the evaluation of chronic cough. The onset of ACE inhibitor-induced cough ranges from within hours of the first dose to months after the initiation of therapy. Resolution typically occurs within 1 to 4 weeks after the cessation of therapy, but cough may linger for up to 3 months. The only uniformly effective treatment for ACE inhibitor-induced cough is the cessation of treatment with the offending agent. The incidence of cough associated with therapy with angiotensin-receptor blockers appears to be similar to that of the control drug. In a minority of patients, cough will not recur after the reintroduction of ACE inhibitor therapy.

Conclusions:

In a patient with chronic cough, ACE inhibitors should be considered as wholly or partially causative, regardless of the temporal relation between the initiation of ACE inhibitor therapy and the onset of cough. Although the cessation of therapy is the only uniformly effective treatment for ACE inhibitor-induced cough, some pharmacologic agents have been shown to attenuate the cough.

Section snippets

RECOMMENDATION

1. In patients presenting with chronic cough, in order to determine that the ACE inhibitor is the cause of the cough, therapy with ACE inhibitors should be discontinued regardless of the temporal relation between the onset of cough and the initiation of ACE inhibitor therapy. The diagnosis is confirmed by the resolution of cough, usually within 1 to 4 weeks of the cessation of the offending agent; however, the resolution of cough may be delayed in a subgroup of patients for up to 3 months.

PATHOGENESIS

The mechanism of ACE inhibitor-induced cough remains unclear. Possible protussive mediators include bradykinin and substance P, which are degraded by ACE and therefore accumulate in the upper airway or lung when the enzyme is inhibited; and prostaglandins, the production of which may be stimulated by bradykinin.1, 14 Bradykinin-induced sensitization of airway sensory nerves has been proposed as a potential mechanism of ACE inhibitor-induced cough.14 Some evidence has suggested that the

TREATMENT

The only uniformly effective intervention for ACE inhibitor-induced cough is the cessation of therapy with the offending agent. Numerous small studies have evaluated various drugs as potential therapies (Table 1). Agents demonstrating the ability to attenuate cough due to ACE inhibitors in randomized, double-blind, placebo-controlled trials include inhaled sodium cromoglycate,19 theophylline,20 sulindac,21 indomethacin,22 the calcium-channel antagonists amlodipine and nifedipine,22 ferrous

RECOMMENDATIONS

2. In patients presenting with chronic ACE inhibitor-induced cough, discontinue therapy with the drug because it is the only uniformly effective treatment. Quality of evidence, low; net benefit, substantial; grade of recommendation, B

3. In patients whose cough resolves after the cessation of therapy with ACE inhibitors, and for whom there is a compelling reason to treat with these agents, a repeat trial of ACE inhibitor therapy may be attempted. Quality of evidence, fair; net benefit,

RECOMMENDATION

5. In patients in whom persistent or intolerable ACE inhibitor-induced cough occurs, therapy should be switched, when indicated, to an ARB, with which the incidence of associated cough appears to be similar to that for the control drug, or to an appropriate agent of another drug class. Quality of evidence, good; net benefit, substantial; grade of recommendation, A

SUMMARY OF RECOMMENDATIONS

  • 1.

    In patients presenting with chronic cough, in order to determine that the ACE inhibitor is the cause

REFERENCES (29)

  • ZH Israili et al.

    Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy: a review of the literature and pathophysiology

    Ann Intern Med

    (1992)
  • D Ravid et al.

    Angiotensin-converting enzyme inhibitors and cough: a prospective evaluation in hypertension and in congestive heart failure

    J Clin Pharmacol

    (1994)
  • CJ Mello et al.

    The predictive values of the character, timing, and complications of chronic cough in diagnosing its cause

    Arch Intern Med

    (1996)
  • RS Irwin et al.

    Chronic cough: the spectrum and frequency of causes, key components of the diagnostic evaluation, and outline of specific therapy

    Am Rev Respir Dis

    (1990)
  • NA Smyrnios et al.

    Chronic cough with a history of excessive sputum production: the spectrum and frequency of causes and key components of the diagnostic evaluation, and outcome of specific therapy

    Chest

    (1995)
  • I Os et al.

    Female preponderance for lisinopril-induced cough in hypertension

    Am J Hypertens

    (1994)
  • DM Coulter et al.

    Cough associated with captopril and enalapril

    BMJ

    (1987)
  • E Strocchi et al.

    Cough during treatment with angiotensin converting enzyme inhibitors: analysis of predisposing factors

    Drug Invest

    (1992)
  • GR Gibson

    Enalapril-induced cough

    Arch Intern Med

    (1989)
  • J Woo et al.

    A high incidence of cough associated with combination therapy of hypertension with isradipine and lisinopril in Chinese subjects

    Br J Clin Pract

    (1991)
  • KS Woo et al.

    High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese

    Br J Clin Pharmacol

    (1995)
  • AH Morice et al.

    Angiotensin-converting enzyme and the cough reflex

    Lancet

    (1987)
  • Y Lacourciere et al.

    Effects of modulators of the renin-angiotensin-aldosterone system on cough

    J Hypertens

    (1994)
  • AJ Fox et al.

    Bradykinin-evoked sensitization of airway sensory nerves: a mechanism for ACE-inhibitor cough

    Nat Med

    (1996)
  • Cited by (342)

    • Angiotensin-Converting Enzyme Inhibitor–Induced Angioedema

      2023, Immunology and Allergy Clinics of North America
    • Guidelines for the management of chronic cough in adults

      2023, Revue des Maladies Respiratoires
    View all citing articles on Scopus

    Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/misc/reprints.shtml).

    View full text